Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging

被引:35
作者
Bates, David [1 ,2 ]
Abraham, Suraj [1 ]
Campbell, Michael [1 ,3 ]
Zehbe, Ingeborg [1 ,2 ]
Curiel, Laura [1 ,4 ]
机构
[1] Thunder Bay Reg Res Inst, Thunder Bay, ON, Canada
[2] Lakehead Univ, Dept Biol, Thunder Bay, ON P7B 5E1, Canada
[3] Lakehead Univ, Dept Chem, Thunder Bay, ON P7B 5E1, Canada
[4] Lakehead Univ, Dept Phys, Thunder Bay, ON P7B 5E1, Canada
来源
PLOS ONE | 2014年 / 9卷 / 05期
关键词
DTPA-MONOCLONAL ANTIBODY; HUMAN-PAPILLOMAVIRUS; 16; MEMBRANE ANTIGEN; EXTRACELLULAR DOMAIN; NUDE-MICE; MULTIFUNCTIONAL NANOPARTICLES; SIGNAL-TRANSDUCTION; IN-VIVO; TUMOR; THERAPY;
D O I
10.1371/journal.pone.0097220
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study we developed, characterized and validated in vitro a functional superparagmagnetic iron-oxide based magnetic resonance contrast agent by conjugating a commercially available iron oxide nanoparticle, Molday ION Rhodamine-B Carboxyl (MIRB), with a deimmunized mouse monoclonal antibody (muJ591) targeting prostate-specific membrane antigen (PSMA). This functional contrast agent is intended for the specific and non-invasive detection of prostate cancer cells that are PSMA positive, a marker implicated in prostate tumor progression and metastasis. The two-step carbodiimide reaction used to conjugate the antibody to the nanoparticle was efficient and we obtained an elemental iron content of 19586611 per antibody. Immunofluorescence microscopy and flow cytometry showed that the conjugated muJ591: MIRB complex specifically binds to PSMA-positive (LNCaP) cells. The muJ591: MIRB complex reduced cell adhesion and cell proliferation on LNCaP cells and caused apoptosis as tested by Annexin V assay, suggesting anti-tumorigenic characteristics. Measurements of the T2 relaxation time of the muJ591: MIRB complex using a 400 MHz Innova NMR and a multi-echo spin-echo sequence on a 3T MRI (Achieva, Philips) showed a significant T2 relaxation time reduction for the muJ591: MIRB complex, with a reduced T2 relaxation time as a function of the iron concentration. PSMA-positive cells treated with muJ591: MIRB showed a significantly shorter T2 relaxation time as obtained using a 3T MRI scanner. The reduction in T2 relaxation time for muJ591: MIRB, combined with its specificity against PSMA+LNCaP cells, suggest its potential as a biologically-specific MR contrast agent.
引用
收藏
页数:11
相关论文
共 48 条
[1]   Induction of Effective Antitumor Response After Mucosal Bacterial Vector Mediated DNA Vaccination With Endogenous Prostate Cancer Specific Antigen [J].
Ahmad, Sarfraz ;
Casey, Garrett ;
Cronin, Michelle ;
Rajendran, Simon ;
Sweeney, Paul ;
Tangney, Mark ;
O'Sullivan, Gerald C. .
JOURNAL OF UROLOGY, 2011, 186 (02) :687-693
[2]  
[Anonymous], CANADIAN CANC REGIST
[3]  
Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181
[4]   MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles [J].
Artemov, D ;
Mori, N ;
Okollie, B ;
Bhujwalla, ZM .
MAGNETIC RESONANCE IN MEDICINE, 2003, 49 (03) :403-408
[5]   Molecular magnetic resonance imaging with targeted contrast agents [J].
Artemov, D .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 90 (03) :518-524
[6]   Technology Insight: monoclonal antibody imaging of prostate cancer [J].
Bander, NH .
NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (04) :216-225
[7]   Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].
Bander, NH ;
Nanus, DM ;
Milowsky, MI ;
Kostakoglu, L ;
Vallabahajosula, S ;
Goldsmith, SJ .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677
[8]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[9]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[10]  
Bayes M, 2007, Methods Find Exp Clin Pharmacol, V29, P547